Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands
- PMID: 15673844
- DOI: 10.1177/1545968304273201
Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands
Abstract
Drooling is common in patients with neurological disorders. Recently, botulinum toxin type B has been shown to be effective in the treatment of drooling. The authors present a unique case of a 57-year-old man with a history of a brainstem stroke and severe drooling. The patient's parotid and submandibular glands were injected under ultra-sound guidance with botulinum toxin type B. Saliva was collected and quantified before and after the injections by 2 different collection methods: suctioning and dental rolls. Total saliva production decreased by 23.8% after injection of the parotid glands and by 85.8% after submandibular injection compared to the preinjection level. The 2 methods demonstrated similar results. In addition, the patient experienced less drooling and increased participation in therapies without any side effects. This case demonstrates that saliva secretion and drooling can effectively be treated by injections of botulinum toxin type B into the salivary glands.
Similar articles
-
Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.Neuropediatrics. 2008 Aug;39(4):200-4. doi: 10.1055/s-0028-1112115. Epub 2009 Jan 22. Neuropediatrics. 2008. PMID: 19165707 Clinical Trial.
-
Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.J Oral Maxillofac Surg. 2003 Apr;61(4):454-7. doi: 10.1053/joms.2003.50086. J Oral Maxillofac Surg. 2003. PMID: 12684962
-
Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.Laryngoscope. 2004 Oct;114(10):1856-60. doi: 10.1097/00005537-200410000-00033. Laryngoscope. 2004. PMID: 15454785
-
Salivary gland application of botulinum toxin for the treatment of sialorrhea.Med Oral Patol Oral Cir Bucal. 2007 Nov 1;12(7):E511-7. Med Oral Patol Oral Cir Bucal. 2007. PMID: 17978775 Review.
-
Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement.Eur J Neurol. 2010 Aug;17 Suppl 2:109-21. doi: 10.1111/j.1468-1331.2010.03131.x. Eur J Neurol. 2010. PMID: 20633182
Cited by
-
Chaudhuri's Dashboard of Vitals in Parkinson's syndrome: an unmet need underpinned by real life clinical tests.Front Neurol. 2023 May 25;14:1174698. doi: 10.3389/fneur.2023.1174698. eCollection 2023. Front Neurol. 2023. PMID: 37305739 Free PMC article. Review.
-
Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease.Mov Disord. 2009 Apr 15;24(5):635-46. doi: 10.1002/mds.22260. Mov Disord. 2009. PMID: 19205066 Free PMC article.
-
Evidence for the effectiveness of botulinum toxin for sialorrhoea.J Neural Transm (Vienna). 2008;115(4):631-5. doi: 10.1007/s00702-007-0861-y. Epub 2008 Feb 4. J Neural Transm (Vienna). 2008. PMID: 18250951 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources